Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
Looking for a particular Allogene Therapeutics employee's phone or email?
Allogene Therapeutics Questions
The Allogene Therapeutics annual revenue was $25 million in 2026.
David Chang is the President and Chief Executive Officer of Allogene Therapeutics.
267 people are employed at Allogene Therapeutics.
Allogene Therapeutics is based in South San Francisco, California.
The NAICS codes for Allogene Therapeutics are [3254, 541, 54, 325, 32541, 54138, 325414, 32, 5413].
The SIC codes for Allogene Therapeutics are [28, 283].
Top Allogene Therapeutics Employees
-
Susan Lundeen
Chief People Officer at Allogene Therapeutics
Thousand Oaks, CA, US15+ -
Arie Belldegrun
Chairman Of The Board at Allogene Therapeutics
Los Angeles, CA, US11 -
35+
-
Saurav Mahanti
Vice President Information Technology at Allogene Therapeutics
California, United States34 -
Alex Babayan
Vice President at Allogene Therapeutics
Los Angeles, CA, US23 -
21 -
Daniel Hunt
VP, Corporate and Business Development at Allogene Therapeutics
San Francisco, CA, US23 -
23
Related Companies
